Chinese Clinical Oncology

Select

Research progress of the application of chimeric antigen receptor-engineered T lymphocytes for solid cancer

ZHU Tong， WANG Jiejun， ZHOU Wenli.

Abstract （940）

PDF（pc）（914KB）（484）

Save

In recent years， the researches on chimeric antigen receptor（CAR） engineered T lymphocytes in curing cancer have made great progresses. CAR has several technical advantages， such as endowing great targeting ability to CAR-engineered T cells， breaking the state of immune tolerance and so on， which make great progress in curing Hematology. Because of existed off-target effects of solid tumor and the poor penetration of immune cells into the tumor tissue， this application is still in phase I clinical trial. This paper will make a review of the application of CAR enjineered T lymphocyte to some solid tumor experiments.

Related Articles | Metrics

Select

Chinese Clinical Oncology

Abstract （572）

PDF（pc）（1490KB）（2543）

Save

Related Articles | Metrics

Select

Chinese Clinical Oncology

Abstract （2392）

PDF（pc）（895KB）（1638）

Save

Related Articles | Metrics

Select

Current status and prospect of immune checkpoint inhibitors in treatment of advanced soft tissue sarcoma

XUE Luxin, ZHANG Zhifan, LIU Fangcen, WANG Xiaolu, WANG Qin, LIU Baorui, LI Rutian.

Chinese Clinical Oncology 2023, 28 (01): 77-83.

Abstract （256）

PDF（pc）（947KB）（791）

Save

Soft tissue sarcomas (STS) are a rare group of mesenchymal malignancies except bone or cartilage, with a low incidence rate. Patients with advanced STS have limited treatment options, poor prognosis and high mortality. Recently, immune checkpoint inhibitors (ICIs) have made great breakthroughs in the field of tumor therapy, greatly improving the prognosis of patients with various malignancies. However, efficacy of ICIs in the treatment of STS remains unravelled. This review summarizes the role of the ICIs in various sets of advanced STS treatment and provides future research directions, hoping to serve as a reference for clinicians.

Related Articles | Metrics

Select

Chinese Clinical Oncology

Abstract （1762）

PDF（pc）（917KB）（2149）

Save

Related Articles | Metrics

Select

Prevalence and prevention strategies of cervical cancer in the world and China

CAI Huilong, YUAN Weiguang, SUN Huixin.

Chinese Clinical Oncology 2023, 28 (01): 90-93.

Abstract （456）

PDF（pc）（869KB）（830）

Save

The International Agency for Research on Cancer (IARC) estimates 36 cancer incidence rate and mortality rates in 185 countries/regions through GLOBOCAN 2020 database. Globocan2020 database shows that cervical cancer is the fourth largest tumor in women in the world, whether it is morbidity or mortality. The harm of cervical cancer to women's health and its prevention and treatment are important public health issues facing the world. This paper will summarize and compare the incidence and death prevalence of cervical cancer in the world and China from the aspects of population characteristics, regional distribution and time change trend, and combined with the reported human papillomavirus and other risk factors, primary prevention and secondary prevention strategies of cervical cancer, in order to provide scientific clues for the prevention and treatment strategies of cervical cancer in the future.

Related Articles | Metrics

Select

Expert consensus of preventing heart toxicity by anthracycline in China(version 2013)

CSCO,CHS

Chinese Clinical Oncology

Abstract （961）

PDF（pc）（1087KB）（1553）

Save

Related Articles | Metrics

Select

Chinese Clinical Oncology

Abstract （921）

PDF（pc）（1800KB）（1180）

Save

Related Articles | Metrics

Select

Expert consensus of prevention and treament of lymphoma patients with HBV reactivation induced by immune chemotherapy in China

CSCO,CHS, Oncoligst Appraisal Committee of Chinese Medical Doctor Association

Chinese Clinical Oncology

Abstract （959）

PDF（pc）（1085KB）（1221）

Save

标准刊号：	ISSN 1009-0460
	CN 32-1577/R